Previous Close | 5.59 |
Open | 5.63 |
Bid | 5.69 x 800 |
Ask | 5.73 x 2200 |
Day's Range | 5.58 - 5.86 |
52 Week Range | 1.98 - 6.29 |
Volume | |
Avg. Volume | 193,225 |
Market Cap | 240.061M |
Beta (5Y Monthly) | 1.66 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.05 |
Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.92 |
Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Investors should consider stocks like Harvard Bioscience (HBIO), MicroStrategy (MSTR), Meta Platforms (META), InterDigital (IDCC), and Weave Communications (WEAV) in their portfolio if they want to outperform the broader market.
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Harvard Bioscience, Inc. ( NASDAQ:HBIO ) shares have continued their recent momentum with a 39% gain in the last month...
Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023. Presentation schedule is subject to change, please visit www.sidoti.com/events for the most updated version and webinar links.
HOLLISTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Micro Cap Virtual Conference taking place on May 10th, 2023. Mr. Green will present on Wednesday, May 10th at 11:30 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of the Harvard
Shares of Harvard Bioscience (NASDAQ: HBIO), a medical equipment and technology manufacturer and retailer, were up by 16.4% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. Harvard Bioscience sells laboratory equipment to clinical research organizations, pharmaceutical companies, and academic labs -- everything from amino acid analyzers to programmable syringe pumps. The company has two segments: cellular and molecular, and pre-clinical.
Q1 2023 Harvard Bioscience Inc Earnings Call
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
Q1 Revenues of $30 million up 4% over prior year periodQ1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior yearQ1 Adjusted Operating Income of $4.4 million up from $2.4 million prior year HOLLISTON, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2023. First quarter revenues were $30.0 million, up 4% versus $28.8 million in Q1 ‘22. Reported revenue i
Designed to meet the pre-clinical testing needs of CROs, pharma and research laboratoriesHOLLISTON, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the initial order for the Company’s new high-capacity behavioral monitoring system for pre-clinical applications. This initial order, which was placed by one of the Company’s large contract research organization (CRO) customers, is scheduled for delivery in the fourth quarter of 2023.
HOLLISTON, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2023 before the market opens on April 25, 2023, and will hold a conference call to discuss the results at 9:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-
Harvard Bioscience, Inc. ( NASDAQ:HBIO ), is not the largest company out there, but it received a lot of attention from...
Key Insights Using the 2 Stage Free Cash Flow to Equity, Harvard Bioscience fair value estimate is US$6.43 Current...
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 22-23, 2023.
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Virtual Investor Conference taking place on March 22-23, 2023. Mr. Green will present on Wednesday, March 22 at 10:00 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of the Harv
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023. Mr. Green will present on Tuesday, March 21 at 9:45 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of
Q4 2022 Harvard Bioscience Inc Earnings Call
HOLLISTON, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparable prior year period, including a negative currency impact of $1.0 million. During the quarter ended December 31, 2022, our cellular and molecular product revenues were roughly flat after adjusting for currency impacts. Pre-
Harvard Bioscience, Inc. ( NASDAQ:HBIO ) is possibly approaching a major achievement in its business, so we would like...
HOLLISTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2022 before the market opens on March 9, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who want to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who want to join the audio-only web
Every investor in Harvard Bioscience, Inc. ( NASDAQ:HBIO ) should be aware of the most powerful shareholder groups. The...
HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Michael Rossi, the Company’s chief financial officer and treasurer, effective December 31, 2022. The Company has appointed Jennifer Cote, the Company’s vice president of global finance, as its interim chief financial officer and treasurer, effective upon Mr. Rossi’s resignation. Mr. Rossi will remain with the Company through May 10, 2023 to provide transi
Even if it's not a huge purchase, we think it was good to see that James Green, the President of Harvard Bioscience...